Halozyme Therapeutics, Inc. has entered into a definitive agreement to acquire Antares Pharma, Inc.  for approximately $960 million.   The combined companies will create a leading drug delivery and specialty product company. The Antares business consists of differentiated, royalty revenue generating auto injector platform business that offers broad licensing opportunity, and a commercial business, with three proprietary commercial products.   Financial and Strategic Benefits include:    Th...